Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Which has higher earnings and valuation, RXRX or ASND?

Recursion Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$44.58M	57.23	-$328.07M	-$1.53	-4.27
Ascendis Pharma A/S	$327.43M	23.75	-$521.07M	-$8.08	-15.86

Does the media favor RXRX or ASND?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 7 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.69 beat Recursion Pharmaceuticals' score of 0.28 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, RXRX or ASND?

Recursion Pharmaceuticals has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Does the MarketBeat Community prefer RXRX or ASND?

Ascendis Pharma A/S received 411 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 66.57% of users gave Ascendis Pharma A/S an outperform vote while only 56.86% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 29 56.86%	Underperform Votes 22 43.14%
Ascendis Pharma A/S	Outperform Votes 440 66.57%	Underperform Votes 221 33.43%

Do analysts rate RXRX or ASND?

Recursion Pharmaceuticals currently has a consensus price target of $8.75, suggesting a potential upside of 34.00%. Ascendis Pharma A/S has a consensus price target of $192.07, suggesting a potential upside of 49.90%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Do institutionals & insiders believe in RXRX or ASND?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is RXRX or ASND more profitable?

Ascendis Pharma A/S has a net margin of -130.33% compared to Recursion Pharmaceuticals' net margin of -579.52%. Ascendis Pharma A/S's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%
Ascendis Pharma A/S	-130.33%	N/A	-48.77%

Summary

Ascendis Pharma A/S beats Recursion Pharmaceuticals on 11 of the 18 factors compared between the two stocks.